For Diabetics, a New Insulin Inhaler Could Replace Shots as Early as 2014 (Businessweek) The long promise of insulin that diabetics can inhale appears to be moving closer to the market. An inhalable insulin powder called Afrezza showed positive results for controlling diabetes in a late-stage clinical trial, the drug’s maker, MannKind Corporation (NASDAQ:MNKD), reported today. Pharmaceutical companies have been working on inhalable insulin for a long time on the theory that diabetics would prefer to puff on an inhaler than give themselves a shot. In 2007, Pfizer (PFE) stopped selling its Exubera insulin powder because of weak sales after less than two years on the market. Exubera never gained traction, largely because insurers wouldn’t pay for it, saying it was too expensive and didn’t work for many patients. Eli Lilly & Co. (LLY) and Novo Nordisk (NVO) both ended inhaled insulin research programs in 2008.
MannKind Corp. Rating Reiterated by Zacks (MNKD) (Watch List News) MannKind Corporation (NASDAQ:MNKD)‘s stock had its “neutral” rating reaffirmed by Zacks in a research report issued to clients and investors on Wednesday, AR Network reports. They currently have a $7.25 target price on the stock. Zacks‘ price objective points to a potential upside of 5.69% from the stock’s previous close. Zacks‘ analyst wrote, “MannKind’s second quarter 2013 net loss of $0.16 per share was narrower than the year-ago loss of $0.23 but wider than the Zacks Consensus Estimate of a loss of $0.15. We expect investor focus to remain on Afrezza.
Investors Purchase High Volume of MannKind Corp. Put Options (MNKD) (Watch List News) Shares of MannKind Corporation (NASDAQ:MNKD) was the recipient of unusually large options trading activity on Monday. Traders acquired 11,596 put options on the company, Stock Ratings Network reports.This is an increase of approximately 114% compared to the average volume of 5,418 put options. In other MannKind Corp. news, CFO Matthew J. Pfeffer sold 10,000 shares of MannKind Corp. stock in a transaction that occured on Thursday, August 1st. The stock was sold at an average price of $8.00, for a total transaction of $80,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission.
Healthcare Stocks in Spotlight – MannKind Corporation (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Merck & Co., Inc. (NYSE:MRK) (Techsonian) King Penny Stocks is an elite financial community for investors and traders alike who are looking to potentially gain financial freedom through the markets on undervalued companies and “in-play” momentum penny stocks. Today We bring special trend analysis of following stocks: MannKind Corporation (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Merck & Co., Inc. (NYSE:MRK). MannKind Corporation reported the gain of +17.93% to $8.09 in the mid-day trading session with the total traded volume of 31.37 million shares more than the average volume of 6.37 million. MNKD has market cap of 2.45 billion and its beta value stands at 1.41 times. MannKind Corporation (MannKind) is a development-stage biopharmaceutical company.
MannKind Diabetes Drug Tops Expectations in Study, Shares Soar (Fox Business) Shares of MannKind Corporation (NASDAQ:MNKD) climbed 20% Wednesday morning after the company revealed positive late-stage trial results for its experimental diabetes drug. The Valencia, Calif.-based drug developer said two Phase III clinical studies for Afrezza, an ultra rapid-acting mealtime insulin therapy administered through MannKind’s next-generation inhaler, met their primary endpoints. The results "will form the basis of an amendment to our new drug application for AFREZZA, which we expect to submit to the Food and Drug Administration early in the fourth quarter of this year,” MannKind CEO Alfred Mann said in a statement.